Immunotoxin Therapy for Cancer

JAMA: The Journal of the American Medical Association

Volumn 269, Issue 1, 1993, Pages 78-81

  Pai, Lee H ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; IMMUNOTOXIN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; DRUG MECHANISM; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BACTERIAL TOXINS; DNA, RECOMBINANT; DRUG DESIGN; EXOTOXINS; FORECASTING; HUMAN; IMMUNOTOXINS; NEOPLASMS; PSEUDOMONAS AERUGINOSA;

EID: 0027441541     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03500010088038     Document Type: Article

References (26)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature. 1975;256:495-497.
2. Frankel AE, ed. Immunotoxins. Philadelphia, Pa: Kluwer Academic Publications; 1989.
3. Pastan I, Willingham MC, FitzGerald DJ. Immunotoxins. Cell. 1986;47:641-648.
4. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. Redesigning major poisons to create antitumor reagents. Science. 1987;238:1098-1104.
5. Olsnes S, Sandvig K. Entry of polypeptide toxins into mammalian cells. In: Pastan I, Willingham MC, eds. Endocytosis. New York, NY: Plenum Press; 1985:195-234.
6. Blakey DC, Watson GJ, Knowles PP, Thorpe PE. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and antithy 1.1 antibody. Cancer Res. 1987;47:947-952.
7. Thorpe PE, Wallace PM, Knowles PP, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Res. 1988;48:6393-6403.
8. Piatak M, Lane JA, Laird W, Bjorn MJ, Wang A, Williams M. Expression of soluble and fully functional ricin A chain in E coli is temperature sensitive. J Biol Chem. 1988;263:4837-4843.
9. Draper RK, Simon MI. The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence of lysosomal involvement. J Cell Biol. 1980;87:849-854.
10. Blewitt MG, Chung LA, London E. Effect of pH on the conformation of diphtheria toxin and its implication for membrane penetration. Biochemistry. 1985;24:5458-5464.
11. Allured VS, Collier RJ, Carroll S, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc Nati Acad Sci U S A. 1986;83:1320-1324.
12. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E coli. Cell. 1987;48:129-136.
13. FitzGerald DJ, Morris RE, Saelinger CB. Receptor-mediated internalization of Pseudomonas toxin by mouse fibroblasts. Cell. 1980;21:867-873.
14. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37 kd toxin fragment that is translocated to the cytosol. J Biol Chem. 1990;265:20678-20685.
15. Pastan I, Chaudhary V, FitzGerald D. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem. 1992;61(suppl):K31-K54.
16. Willingham MC, FitzGerald DJ, Pastan I. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc Nati Acad Sci U S A. 1987;84:2474-2478.
17. FitzGerald DJ, Willingham MC, Pastan I. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci U S A. 1986;83:6627-6630.
18. Pai LH, Bookman MA, Ozols RF, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol. 1991;9:2095-2103.
19. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 1991; 51:3781-3787.
20. Kondo T, FitzGerald D, Chaudhary VK, Adhya S, Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988;263: 9470-9475.
21. Batra JK, Jinno Y, Chaudhary VK, et al. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Nati Acad Sci U S A. 1989;86:8545-8549.
22. Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc Nati Acad Sci U S A. 1991;88:3358-3362.
23. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-397.
24. Brinkmann U, Pai LH, FitzGerald DJ, Willingham MC, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A. 1991;88:8616-8620.
25. Pastan I, FitzGerald DJ. Recombinant toxins for cancer treatment. Science. 1992;254:1173-1177.
26. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589-596.